Izotropic Corporation (IZOZF)
USD 0.03
(-10.45%)
USD 0.03
(-10.45%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 1.56 Million CAD | -70.64% |
| 2023 | 5.33 Million CAD | -19.26% |
| 2022 | 6.6 Million CAD | 32.77% |
| 2021 | 4.97 Million CAD | 330.52% |
| 2020 | 1.15 Million CAD | 190.02% |
| 2019 | 398.53 Thousand CAD | -43.5% |
| 2018 | 705.4 Thousand CAD | 870.45% |
| 2017 | 72.68 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 230.53 Thousand CAD | -66.45% |
| 2024 FY | 1.64 Million CAD | -69.25% |
| 2024 Q4 | 322.75 Thousand CAD | 40.0% |
| 2024 Q1 | 429.37 Thousand CAD | -63.58% |
| 2024 Q2 | 687.1 Thousand CAD | 60.02% |
| 2023 Q3 | 1.91 Million CAD | 48.2% |
| 2023 Q4 | 1.17 Million CAD | -38.51% |
| 2023 FY | 5.33 Million CAD | -19.26% |
| 2023 Q1 | 964.27 Thousand CAD | -40.58% |
| 2023 Q2 | 1.29 Million CAD | 34.17% |
| 2022 Q2 | 2.53 Million CAD | 106.71% |
| 2022 Q1 | 1.22 Million CAD | -35.73% |
| 2022 FY | 6.6 Million CAD | 32.77% |
| 2022 Q4 | 1.62 Million CAD | 30.43% |
| 2022 Q3 | 1.24 Million CAD | -50.85% |
| 2021 Q3 | 2.37 Million CAD | 538.67% |
| 2021 Q2 | 371.31 Thousand CAD | -17.27% |
| 2021 FY | 4.97 Million CAD | 330.52% |
| 2021 Q1 | 448.81 Thousand CAD | -25.83% |
| 2021 Q4 | 1.9 Million CAD | -19.66% |
| 2020 FY | 1.15 Million CAD | 190.02% |
| 2020 Q4 | 605.14 Thousand CAD | 143.13% |
| 2020 Q3 | 248.89 Thousand CAD | 60.18% |
| 2020 Q1 | 146.42 Thousand CAD | 5.64% |
| 2020 Q2 | 155.38 Thousand CAD | 6.12% |
| 2019 Q1 | 87.91 Thousand CAD | -43.32% |
| 2019 Q2 | 94.39 Thousand CAD | 7.37% |
| 2019 Q4 | 138.6 Thousand CAD | 78.55% |
| 2019 FY | 398.53 Thousand CAD | -43.5% |
| 2019 Q3 | 77.62 Thousand CAD | -17.76% |
| 2018 Q1 | 72.07 Thousand CAD | 198985.74% |
| 2018 Q2 | 409.22 Thousand CAD | 467.76% |
| 2018 Q3 | 68.98 Thousand CAD | -83.14% |
| 2018 Q4 | 155.11 Thousand CAD | 124.85% |
| 2018 FY | 705.4 Thousand CAD | 870.45% |
| 2017 Q1 | 14.83 CAD | 0.0% |
| 2017 Q4 | 36.20 CAD | 138.03% |
| 2017 FY | 72.68 Thousand CAD | 0.0% |
| 2017 Q2 | 22.10 CAD | 49.03% |
| 2017 Q3 | 15.21 CAD | -31.19% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -49.315% |
| Arrayit Corporation | 6.19 Million USD | 74.727% |
| Atlantic International Corp. | 5.57 Million USD | 71.921% |
| Biocept, Inc. | 29.4 Million USD | 94.673% |
| Bioqual, Inc. | 7.44 Million USD | 78.972% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -102.853% |
| DermTech, Inc. | 104.01 Million USD | 98.494% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 99.059% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 93.077% |
| iMD Companies, Inc. | 151.8 Thousand USD | -931.766% |
| IDenta Corp. | 662.97 Thousand USD | -136.255% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 92.258% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -3928.479% |
| InVitro International | 661.32 Thousand USD | -136.845% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 77.933% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -2595.335% |
| Medical Imaging Corp. | 1.91 Million USD | 18.087% |
| NovelStem International Corp. | 3.53 Million USD | 55.726% |
| Optigenex Inc. | 1.28 Million USD | -21.621% |
| PharmChem, Inc. | 2.93 Million USD | 46.565% |
| Proteome Sciences plc | 3.26 Million USD | 52.071% |
| Response Genetics, Inc | 25.31 Million USD | 93.814% |
| Rennova Health, Inc. | 7.67 Million USD | 79.599% |
| RushNet, Inc. | 1.78 Million USD | 12.463% |
| ScreenPro Security Inc. | 3.23 Million USD | 51.641% |
| Stella Diagnostics Inc. | 11.42 Million USD | 86.293% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 78.669% |
| Todos Medical Ltd. | 14.05 Million USD | 88.858% |